Le Lézard
Classified in: Health
Subjects: TDS, ANW, FVT

Heska Announces its Annual Meeting of Stockholders on May 4, 2022


LOVELAND, Colo., April 14, 2022 /PRNewswire/ -- Heska Corporation (NASDAQ: HSKA) ("Heska" or the "Company"), a leading global provider of advanced veterinary diagnostic and specialty solutions, announces its 2022 Annual Meeting of Stockholders. The virtual event is scheduled for 9 a.m. MT / 11 a.m. ET on Wednesday, May 4, 2022. Stockholders of record as of March 7, 2022, are entitled to notice of, participate in and vote at, the annual meeting.  All stockholders are encouraged to vote on the proposed matters before the Annual Meeting by proxy as described in the Company's proxy materials provided to stockholders. 

2022 Annual Meeting of Stockholders
Wednesday, May 4, 2022
9 a.m. MT/11 a.m. ET
To access the webcast, please visit: http://meetnow.global/M7WVHGD.
The webcast replay will be archived on www.heska.com for 90 days following the event.

About Heska

Heska Corporation (NASDAQ: HSKA) manufactures, develops and sells advanced veterinary diagnostics, informatics, and specialty healthcare solutions through its two business segments: North America and International. Both segments include Point of Care Lab testing instruments and consumables, digital imaging products, software and services, data services, allergy testing and immunotherapy, and single-use offerings such as in-clinic diagnostic tests and heartworm preventive products. The North America segment also includes private label vaccine and pharmaceutical production for third-parties, primarily for herd animal health. For more information, please visit www.heska.com.

 

SOURCE Heska Corporation


These press releases may also interest you

at 01:24
Sedana Medical completes patient recruitment for INSPiRE-ICU 1 clinical trial in the US
Sedana Medical AB (publ) announces that all 235 randomized patients have been recruited for its INSPiRE-ICU 1 phase III clinical trial in the United States. Concurrently, the identical INSPiRE-ICU 2 trial is nearing completion, with 23 of 235...

at 01:17
Essity's Interim Report, Quarter 1, 2024
Quarter 1, 2024 - High profitability and strong cash flow Net sales decreased 4.1% to SEK 34,850m (36,352)Organic growth amounted to -4.0%, of which volume accounted for -1.8% and price/mix -2.2%. Excluding restructuring and exited contracts, volumes...

at 00:05
ImmunityBio Announces Positive Overall Survival Results of Anktiva Combined With Checkpoint Inhibitors in Non-Small Cell Lung Cancer; Meeting Scheduled with FDA to Discuss Registration Path for ANKTIVA in Lung Cancer
ImmunityBio, Inc. , an immunotherapy company, today announced positive overall survival results in the QUILT 3.055 study of 2nd- and 3rd-line NSCLC patients who progressed after checkpoint inhibitor therapy (pembrolizumab, nivolumab, or atezolizumab)...

at 00:05
Few small SUVs excel in new IIHS front crash prevention test
The Insurance Institute for Highway Safety is updating its vehicle-to-vehicle front crash prevention test to address crashes that occur at higher speeds and those in which the struck vehicle is a motorcycle or large truck. Only one of the first 10...

at 00:00
Nutriessential expands globally to Oceania, Asia and the Gulf
Nutriessential.com recently announced its expansion into Oceania, Asia, and the Gulf. The company has been providing science-backed GMP-certified supplements in the US, Europe and Canada since 2005 and decided to expand owing to rising global demands...

24 avr 2024
Summit Clinical Research Statement on Co-Founder and Chairman Dr. Stephen Harrison
Summit Clinical Research LLC ("Summit") is deeply saddened by the death of Co-Founder and Chairman Dr. Stephen Harrison. Summit mourns Dr. Harrison and extends its heartfelt condolences to his family and loved ones.   During an illustrious 30-year...

More news about Health...


News published on and distributed by: